Salusin-β mediate neuroprotective effects for Parkinson's disease

Biochem Biophys Res Commun. 2018 Sep 10;503(3):1428-1433. doi: 10.1016/j.bbrc.2018.07.059. Epub 2018 Jul 13.

Abstract

Neuropeptides, small peptides found in many mammalian brain, play key roles in communicating with each other to modulate neuronal activity. Here, we reported that endogenous neuropeptide salusin-β has neuroprotective effects on the midbrain dopamine neurons and can be used as an effective therapeutic treatment for Parkinson's disease (PD). We found that the MrgprA1 receptor mediates the neuroprotective effects of salusin-β on the midbrain dopamine neurons. Importantly, intranasal administration of salusin-β in a PD mouse model show the neuroprotection of dopaminergic neurons and increased the survival of midbrain dopamine neurons. Furthermore, inhibition of the salusin-β receptor, MrgprA1, abolished the neuroprotective effects induced by salusin-β. Taken together, these results demonstrate the novel role of salusin-β in the central nervous system and salusin-β can be used as a novel therapeutic to effectively treat PD.

Keywords: Neuropeptide; Neuroprotective effect; Parkinson's disease; Salusin-β.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cells, Cultured
  • Disease Models, Animal
  • Dopaminergic Neurons / drug effects*
  • Dopaminergic Neurons / metabolism
  • HEK293 Cells
  • Humans
  • Intercellular Signaling Peptides and Proteins / administration & dosage
  • Intercellular Signaling Peptides and Proteins / metabolism*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Neuroprotective Agents / administration & dosage
  • Neuroprotective Agents / metabolism*
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / metabolism
  • Parkinson Disease / pathology

Substances

  • Intercellular Signaling Peptides and Proteins
  • Neuroprotective Agents
  • TOR2A protein, human